Direct pharmacological targeting of RAC1 by chlorogenic acid: A novel therapeutic approach for mesangial proliferative glomerulonephritis. (PubMed, Acta Pharm Sin B) - Sep 22, 2026 - "Significantly, as a novel natural RAC1 inhibitor, CGA disrupts mesangial-macrophage crosstalk by dual suppression of regional immunity and cellular proliferation, thus conferring renal protection in MsPGN models. Our findings highlight CGA as a promising pharmacotherapy, offering a mechanism-driven, natural product-based strategy to mitigate MsPGN progression."
Journal • Chronic Kidney Disease • Glomerulonephritis • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • CD36 • IL1B • IL6 • RAC1 • SCARB1 • TNFA
|
|
Chunru Shi; Dan Pan; Fei Peng; Guangyan Cai; Jiaona Liu; Jiayi He; Jie Wu; Jie Zhang; Jikai Xia; Lingling Wu; Ping Li; Quan Hong; Ran Liu; Shuwei Duan; Tiantian Wang; Xiangmei Chen; Xu Wang; Yena Zhou; Yilun Qu; Yinghua Zhao; Yingjie Zhang; Yong Wang
|